Harmony 2017

Prof Hehlmann speaks with ecancer about collation and interrogation of data gathered through the HARMONY project. He considers how data must be managed between international collaborators, and workgroup partners at different stages of the project.

Prof Martinelli about work package 5 of HARMONY, focussed on modelling omics data gathered through the project. He considers how genome data could inform patient treatments, and how the project can produce new clinical models, and function as a new co-operative model of co-operation, data analysis and drug testing.

Mr Salimullah speaks with ecancer about the founding and goals of the HARMONY project. He highlights current barriers to drug access, and emphasises the benefit to patients, providers and partners through collaboration with the wealth of data available through the project. Mr Salimullah outlines the work packages within HARMONY, and looks forward to the ongoing research of project partners.

Prof Bullinger speaks with ecancer about Work Package II, a project within HARMONY focused on the focused and interlinked research into haematological malignancies. He describes the uniqueness of the project in uniting many disciplines and stakeholders, and considers how the data generated from the project can be analysed with deeper dimensions of disease subtype, evolution, and progression. Prof Bullinger notes the HARMONY project is only at its inception, and looks forward to pilot studies producing results within the next few years.

Mr Navajo speaks with ecancer about storage, coherence and concordance of data gathered by international partners contributing to the HARMONY project. Considering the experience of GMV in managing data storage across different industries, he emphasises the collaborative nature of HARMONY as one that can deliver results with patient benefit at the forefront.

Mr Salimullah speaks with ecancer about the work of Novartis with the HARMONY project. He outlines the rationale behind the joint effort, bringing together 51 partners from 11 European countries, including 7 pharmaceutical companies.

Dr Hernandez speaks with ecancer about his work as a lead coordinator of HARMONY. He outlines the goals and timeline of the project, working with 'big data' sourced from multiple international clinics and inter-disciplinary partners, with consideration of patient-focussed outcomes.

Dr Bacon meets with ecancer to discuss how the industry collaboration through the HARMONY project aims to improve patient quality of life in haemato-oncology. She considers the benefit to patients within the 7 diseases addressed by the project, and for others, and how the volume of data gathered can be managed.

Dr Butler speaks with ecancer about his work on the legal, ethics and governance unit within the HARMONY project. He describes the varying field of international contribution, attribution and compliance across the many stakeholders in the project, and considers the legal/ethical framework through which patient data is anonymised. Looking forward to pilot projects and further research, Dr Butler outlines the scientific, procedural and legal rigour that will assess data gathered.

Dr Schoonen speaks with ecancer about the scalability of data integration and analysis as part of the HARMONY project. She describes the collaborative nature of the project, and looks forward to when this data might translate into actionable advances for patients.

Dr Fernandez speaks with ecancer about industry collaboration in the HARMONY project. He highlights the valuable contribution possible through the project, which brings together 51 partners from 11 European countries, including 7 pharmaceutical companies, and puts emphasis on improving patient access to trials.

Dr Sanz speaks with ecancer about his involvement in HARMONY, acting as a public lead coordinator and developing patient involvement from the project's inception. The project already works with 51 partners from 11 European countries, including 7 pharmaceutical companies, and Dr Sanz expects this number to grow as the project progresses. Considering the volume and quality of data that will be generated through the project, Dr Sanz explains the different staging and purposes of work groups within the framework of HARMONY what will assure rigorous, regulated analysis of data.

Jan Geissler speaks with ecancer about patient participation in HARMONY through an advocacy work package. He outlines patient involvement at different stages in this project and others, with hopes for early, consistent involvement in future research.

Christina Donatti speaks with ecancer about collaborative data harmonisation in the HARMONY project. She emphasises data security and access as the focus of multiple stakeholders across the project, with work packages facilitating collaboration and research to make the most of the wealth of data available.

Carin Smand speaks with ecancer about work package 7 of HARMONY, focussing on communication, dissemination and training. She describes the essential roles of internal and external communications for the project, which will be shared with Novartis, and how the existing contacts of the EHA can facilitate contribution from an international network of experts across many industries.

Dr Druml speaks with ecancer about the Ethics, Law and Regulatory Affairs work package within HARMONY. She describes how the data gathered, and its transferal the project, must be subject to international data protection laws, and that every part of research must be robust, rational and regulator-approved.